HOME > ARCHIVE
ARCHIVE
- R&D NEWS IN BRIEF
December 5, 2005
- Clopidogrel, Silodosin Recommended for Approval
December 5, 2005
- MEDICAL DEVICE NEWS IN BRIEF
December 5, 2005
- Chuikyo Recommends Approval of 4 Ingredients/6 Products
December 5, 2005
- New Medical Materials Should Be Listed 4 Times a Year: Device Industry
December 5, 2005
- Committee Approves Basic Proposal for Next Revision of Med. Fees
December 5, 2005
- 58% of Pharmacists Have Been Asked to Dispense Generics: Survey
December 5, 2005
- Approval of 3 New Products Recommended
December 5, 2005
- Only Stably Supplied Generics Should Be Covered by Insurance: Mr Futagawa
December 5, 2005
- Social Security Spending Needs Further Cuts
December 5, 2005
- Economic Effects of Generics Depend on Their Efficacy: Research Result
December 5, 2005
- MOF's Council Proposes Considerable Cut in Medical Fees
December 5, 2005
- Generics' Brand Names Are Confusing: Prof. Sato of Chuo Univ.
November 28, 2005
- BUSINESS NEWS IN BRIEF
November 28, 2005
- Artz to Grow Despite Severer Competition: Mr Mizutani of Seikagaku Corp.
November 28, 2005
- 1st 3 QTRS BUSINESS RESULTS
November 28, 2005
- SEMIANNUAL BUSINESS RESULTS -2-
November 28, 2005
- Equal Partnership Needed between Investigators, Monitors and the CRC: JCROA Symposium
November 28, 2005
- SEMIANNUAL BUSINESS RESULTS
November 28, 2005
- SEMINAR
November 28, 2005
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
